Jennifer Gershman, PharmD, CPh

Tecentriq and Keytruda may also be eventually approved as adjuvant therapies.

Developers of the drug express disappointment but plan to seek meetings with regulators in hopes of reviving the application.

The confirmatory trial of one of the approved drugs, Pepaxto, was halted when data suggested it was associated with a higher mortality rate.

At this time, two of three conferences have been reverted to a in-person and virtual format. This includes The American Urological Association (AUA) 2021 Annual Meeting and the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.

NCCN adds Rylaze to guidelines soon after was approved by the FDA and a British company reports positive results for its CAR-T therapy.

The Society for Immunotherapy of Cancer (SITC) released guidelines based on FDA approved immune checkpoint inhibitors (ICIs) for the treatment of urothelial cancer arising from the bladder and other areas of the urinary tract. The guidelines were based around therapies such as the programmed cell death protein 1 (PD-1) inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) and the programmed cell death ligand 1 (PD-L1) inhibitors, Tecentriq (atezolizumab), Bavencio (avelumab) and Imfinzi (durvalumab).

New research and updated treatment guidelines add to knowledge base on this rare blood cancer.

According to the American Urological Association, 72.5% of urologists used Advanced Practice Providers in their practice and these healthcare providers performed a variety of procedures such as a cystoscopy (procedure examining bladder lining), which assists in the diagnosis of bladder cancer. Evidence shows patients have demonstrated a growing acceptance of APPs in urology practice settings.

The Leukemia & Lymphoma Society is providing grants to increase trial enrollment of ethnic and racial minorities.

Researchers identified being Black and of the female gender as the strongest predictors of late-stage diagnosis.

Researchers are making progress in identifying drugs that target certain mutations.

NCCN recommends Brukinsa for CLL/SLL even though it is FDA-approved for mantel cell lymphoma.

Tumors glow pink under blue light.

A virtual summit on urothelial cancers is scheduled for October.

Oncology Analytics senior vice president Laura Bobolt discusses the new indication for Trodelvy and other matters.

The antibody-conjugate is also approved as a treatment for metastatic triple negative breast cancer.

Drug would mean a nonsurgical treatment option for people with upper tract urothelial cancer.

COVID-19 vaccine is safe — and more than a little advisable — for people with urothelial cancer, says a clinical pharmacist at the VA Pittsburgh Healthcare System.

After accelerated approval, both drugs fall short of overall survival endpoint. They will stay on the market for other indications.

New drug may be a treatment option for people with the sixth most common type of cancer.

There are a variety of medications being studied for the COVID-19, and the possible treatment landscape is rapidly evolving.

The successor, Oncology Care First, will likely include two tracks with downside risk right from the start.

The new and proposed federal regulations, as well as state laws, that are trending across the United States.

Here are the top drugs expected to be approved this year and their financial impact.

A program that balances scientific advances and cost, oncology clinical pathways can be an important tool for improving quality of care.

Pain management drugs in phase 3 development show promise as abuse-deterrent formulations of opioid therapies.

Phase 3 drugs show innovative approaches to cancer treatment.

MS is in need of new medications-these could be the future.